Clinical Trials

You are here

Clinical Trials

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

,
,
,
,
2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know OncTalk
The Global Resource for Advancing Cancer Education (GRACE), in partnership with Georgetown University Hospital is pleased to present the videos from the panel discussion "2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know".
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Biopsy/Tissue Collection, Tumor Marker Tests, Targeted Therapy, First-line treatment, Clinical Trials, Investigational Agents, Immunotherapies, Second-line treatment
,
,
Targeted Therapies in Lung Cancer Patient Forum 2017 - Presentations and Handouts
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
Cancer Journey:
Just Diagnosed, In Treatment, Survivorship
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Tumor Marker Tests, 3rd Line and beyond, Targeted Therapy, Molecular Testing, First-line treatment, Scans - PET-CT, etc., Second-line treatment, Clinical Trials, Non Small Cell Lung Cancer
Immunotherapies in Lung Cancer, Part 2: Dr. Brahmer on Ipilumumab, Anti-PD1, Anticancer Viruses, and Talactoferrin
Here's the second presentation from our program on "Immunotherapies for Lung Cancer: Can We Deliver on the Promise?". Our first part was by Dr...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Clinical Trials, Targeted Therapy
Winding Up the Santa Monica Program: Dr. Goss on Implementing Molecular Markers Across Health Care Systems
This is the last of six podcasts produced from the two hour program we did in partnership with the LUNGevity Foundation earlier this year in Santa...
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Clinical Trials, Targeted Therapy, First-line treatment, Molecular Testing
Molecular Markers, Part 5: Dr. David Spigel on Integrating Markers into Clinical Trials
Here's part 5 of our Santa Monica program on Molecular Markers in Advanced NSCLC, closing in on the end of the activity. In this podcast, my friend...
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Clinical Trials, Symptoms

Articles

Overall Management for Stage IIIA Disease
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Chemotherapy, Clinical Trials, Radiation Therapy
What is V20 and Why Do Radiation Dose & Field Size Matter?
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Clinical Trials, Radiation Therapy
The Lung Cancer Master Protocol/SWOG 1400 as a Clinical Trial for a New Era of Molecular Oncology
Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an "umbrella protocol" in which all patients undergo molecular testing and have treatment assigned by the results.
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Clinical Trials, Molecular Testing, Targeted Therapy, Biopsy/Tissue Collection, Scans - PET-CT, etc., Second-line treatment
Clinical Trial Spotlight: Targeting Brain Mets in EGFR Lung Cancer Patients
Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Clinical Trials, Targeted Therapy, Molecular Testing, Symptoms
Clinical Trial Spotlight: Can Epigenetic Priming Improve Efficacy of Immunotherapy in NSCLC?
Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who receive immunotherapy for advanced lung cancer.
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Clinical Trials, Molecular Testing, Targeted Therapy

Community Forum

No Result Found